TITLE

Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis - An Update

AUTHOR(S)
Basso, L. A.; Santos, D. S.
PUB. DATE
October 2005
SOURCE
Medicinal Chemistry Reviews - Online;Oct2005, Vol. 2 Issue 5, p393
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tuberculosis (TB) remains the leading cause of mortality due to a bacterial pathogen, Mycobacterium tuberculosis, and infects approximately 32 % of the world's human population. It is estimated that 8.2 million new TB cases occurred worldwide in the year 2000, with approximately 1.8 million deaths in the same year, and more than 95 % of those were in developing countries. The interruption of centuries of decline in case rates of TB occurred, in most cases, in the late 1980s and involved the USA and some European countries due to increased poverty in urban settings and the immigration from TB high-burden countries. Thus, no sustainable control of TB epidemics can be reached in any country without properly addressing the global epidemic. The reemergence of TB as a potential public health threat, the high susceptibility of human immunodeficiency virus-infected persons to the disease, and the proliferation of multi-drug-resistant (MDR) strains have created much scientific interest in developing new antimycobacterial agents to both treat M. tuberculosis strains resistant to existing drugs, and shorten the duration of short-course treatment to improve patient compliance. Bacterial cell-wall biosynthesis is a proven target for new antibacterial drugs. Mycolic acids, which are key components of the mycobacterial cell wall, are a- alkyl, �-hydroxy fatty acids, with a species-dependent saturated "short" arm of 20-26 carbon atoms and a "long" meromycolic acid arm of 50-60 carbon atoms. The latter arm is functionalized at regular intervals by cyclopropyl, a-methyl ketone, or a-methyl methylethers groups, and, as shown more recently, by unsaturations. The mycolic acid biosynthetic pathway has been proposed to involve five distinct stages: (i) synthesis of C20 to C26 straightchain saturated fatty acids to provide the a-alkyl branch; (ii) synthesis of the meromycolic acid chain to provide the main carbon backbone, (iii) modification of this backbone to introduce other functional groups; (iv) the final Claisen-type condensation step followed by reduction; and (v) various mycolyltransferase processes to cellular lipids. The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan. Pyrazinamide was thought to inhibit fatty acid synthase type I, thereby reducing the synthesis of precursor of mycolic acids. However, current experimental evidence indicates that it has no defined target of action. The main focus of our contribution is on new data describing the mode of action of antitubercular drugs that inhibit mycolic acid biosynthesis, and description of inhibitors of fatty acid synthase type II enzymes as potential lead compounds that may allow the development of new antitubercular agents.
ACCESSION #
18442497

 

Related Articles

  • Recent Advances in New Structural Classes of Anti-Tuberculosis Agents. Nayyar, Amit; Jain, Rahul // Current Medicinal Chemistry;2005, Vol. 12 Issue 16, p1873 

    Tuberculosis (TB) is one of the most devastating diseases primarily due to several decades of neglect, and presents a global health threat of escalating proportions. TB is the second leading infectious cause of mortality today behind only HIV/AIDS. The impetus for developing new structural...

  • Isolation and Identification of Mycobacterium from Extrapulmonary Specimen at NTRL, NIDCH. Mostofa Kamal, S. M.; Ahasan, Ham Nazmul; Ahmed, Sharmin; Ayaz, Kfm; Mahbub, Md. Shahriar; Imran Khan, Mohammad Ashik; Gupta, Ratan Das; Alam, Md. Billal; Miah, Md. Titu // Journal of Medicine;Jul2010, Vol. 11 Issue 2, p128 

    Objective of the study was to see the frequency of isolation of Mycobacterium among different extrapulmonary specimens. The study was carried out at NTRL (National Tuberculosis reference laboratory), NIDCH Bangladesh during January 2008-June 2009. This study was carried out retrospectively by...

  • Development of New Molecular Entities as Potent Antimycobacterial Agents: Synthesis of Substituted Quinazolines. Gangadasu, Hanimi Reddy; Himabindu, V.; Akula, Kalyan Chakravarthy; Shiradkar, Mahendra // Journal of Pharmacy Research;2012, Vol. 5 Issue 5, p2538 

    The re-emergence of tuberculosis infections which are resistant to conventional drug therapy has demonstrated the need for alternative chemotherapy against Mycobacterium tuberculosis. As part of a study to optimize the quinazolines antibacterials against M. tuberculosis, we have prepared several...

  • Isoniazid's Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth. Gumbo, Tawanda; Louie, Arnold; Liu, Weiguo; Ambrose, Paul G.; Bhavnani, Sujata M.; Brown, David; Drusano, George L. // Journal of Infectious Diseases;1/15/2007, Vol. 195 Issue 2, p194 

    Background. It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth. We examined the veracity of this cornerstone belief. Methods. We...

  • Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to Pyrazinamide. Petrella, Stéphanie; Gelus-Ziental, Nathalie; Maudry, Arnaud; Laurans, Caroline; Boudjelloul, Rachid; Sougakoff, Wladimir // PLoS ONE;2011, Vol. 6 Issue 1, p1 

    Pyrazinamidase (PncA) activates the first-line antituberculous drug pyrazinamide into pyrazinoic acid. The crystal structure of the Mycobacterium tuberculosis PncA protein has been determined, showing significant differences in the substrate binding cavity when compared to the pyrazinamidases...

  • Mycobacterium tuberculosis Beijing Genotype, the Netherlands. Borgdorff, Martien W.; de Haas, Petra; Kremer, Kristin; van Soolingen, Dick // Emerging Infectious Diseases;Oct2003, Vol. 9 Issue 10, p1310 

    To determine whether the Beijing genotype of Mycobacterium tuberculosis is emerging in the Netherlands, we collected data on 6,829 patients during 1993 to 2000. Six percent had the Beijing genotype. This genotype was associated with diagnosis in recent years, young age, nationality, and...

  • Empiric Treatment of Community-Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis. Dooley, Kelly E.; Golub, Jonathan; Goes, Fernando S.; Merz, William G.; Sterling, Timothy R. // Clinical Infectious Diseases;6/15/2002, Vol. 34 Issue 12, p1607 

    Fluoroquinolones, which are widely used to treat community-acquired pneumonia, also have excellent in vitro activity against Mycobacterium tuberculosis. A retrospective cohort study was conducted among adults with culture-confirmed tuberculosis to assess the effect of empiric fluoroquinolone...

  • Synthesis and Anti-Mycobacterial Activity of N'-[(E)-(Disubstituted- Phenyl)Methylidene]Isonicotino-Hydrazide Derivatives. Junior, Ivan N.; Lourençco, Maria C. S.; Henriques, Maria das Graças M. O.; Ferreira, Barbara; Vasconcelos, Thatyana R. A.; Peralta, Mônica A.; de Oliveira, Pedro S. M.; Wardell, Solange M. S. V.; de Souza, Marcus V. N. // Letters in Drug Design & Discovery;Nov2005, Vol. 2 Issue 7, p563 

    A series of eight N'-[(E)-(disubstituted-phenyl)methylidene]isonicotino-hydrazide derivatives were synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis, and the activity expressed as the minimum inhibitory concentration (MIC) in mg/mL. Four...

  • Routine Use of Rapid Molecular Methods to Detect Antibiotic Resistance in Mycobacteriumtuberculosis. Matsiota-Bernard, P.; Vrioni, G.; Vogiatzakis, E.; Marinis, E. // European Journal of Clinical Microbiology & Infectious Diseases;Mar2001, Vol. 20 Issue 3, p222 

    The article focuses on the routine use of rapid molecular methods to detect antibiotic resistance in mycobacterium tuberculosis. The re-emergence of tuberculosis, especially multidrug-resistant mycobacterium tuberculosis, over the last few years has emphasized the urgent need for early...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics